文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

瑞美替罗治疗伴肝纤维化NASH的3期随机对照试验

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
PubMed 文献 · N Engl J Med · 2024-01-01

这项正在进行的3期试验纳入经活检确诊NASH且纤维化分期为F1B、F2或F3的成人,按1:1:1随机接受每日一次瑞美替罗80 mg、100 mg或安慰剂。第52周时,两个剂量组的NASH缓解且纤维化未加重、以及纤维化至少改善一个分期且NAFLD活动度评分未加重比例均优于安慰剂;腹泻和恶心在瑞美替罗组更常见,严重不良事件各组相似。

要点

  • 瑞美替罗80 mg和100 mg组NASH缓解且纤维化未加重比例均显著高于安慰剂组。
  • 瑞美替罗80 mg和100 mg组纤维化至少改善一个分期且NAFLD活动度评分未加重比例均显著高于安慰剂组。
  • 腹泻和恶心在瑞美替罗组比安慰剂组更常见;严重不良事件发生率各组相似。

核心结论

  • 瑞美替罗80 mg和100 mg剂量在NASH缓解及肝纤维化至少改善一个分期方面均优于安慰剂。

研究设计与样本

  • 正在进行的3期试验,纳入经活检确诊NASH且纤维化分期为F1B、F2或F3的成人。
  • 患者按1:1:1随机接受每日一次瑞美替罗80 mg、100 mg或安慰剂。
  • 主要分析人群共966例:瑞美替罗80 mg组322例,瑞美替罗100 mg组323例,安慰剂组321例。

主要发现

  • 第52周NASH缓解且纤维化未加重:瑞美替罗80 mg组25.9%,瑞美替罗100 mg组29.9%,安慰剂组9.7%(两个剂量组与安慰剂比较均P<0.001)。
  • 第52周纤维化至少改善一个分期且NAFLD活动度评分未加重:瑞美替罗80 mg组24.2%,瑞美替罗100 mg组25.9%,安慰剂组14.2%(两个剂量组与安慰剂比较均P<0.001)。
  • 低密度脂蛋白胆固醇从基线至第24周变化:瑞美替罗80 mg组-13.6%,瑞美替罗100 mg组-16.3%,安慰剂组0.1%(两个剂量组与安慰剂比较均P<0.001)。
  • 腹泻和恶心在瑞美替罗组比安慰剂组更常见。
  • 严重不良事件发生率:瑞美替罗80 mg组10.9%,瑞美替罗100 mg组12.7%,安慰剂组11.5%。

关键数值与推荐

  • NASH缓解定义为NAFLD活动度评分降低≥2分且纤维化未加重;NAFLD活动度评分范围0至8分,评分越高表示疾病越严重。
  • 纤维化改善定义为纤维化至少降低一个分期且NAFLD活动度评分未加重。
  • 纤维化分期范围从F0(无纤维化)至F4(肝硬化)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo. The two primary end points at week 52 were NASH resolution (including a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by ≥2 points; scores range from 0 to 8, with higher scores indicating more severe disease) with no worsening of fibrosis, and an improvement (reduction) in fibrosis by at least one stage with no worsening of the NAFLD activity score. RESULTS: Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo). Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo). The change in low-density lipoprotein cholesterol levels from baseline to week 24 was -13.6% in the 80-mg resmetirom group and -16.3% in the 100-mg resmetirom group, as compared with 0.1% in the placebo group (P<0.001 for both comparisons with placebo). Diarrhea and nausea were more frequent with resmetirom than with placebo. The incidence of serious adverse events was similar across trial groups: 10.9% in the 80-mg resmetirom group, 12.7% in the 100-mg resmetirom group, and 11.5% in the placebo group. CONCLUSIONS: Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024. PMID: 38324483. doi:10.1056/NEJMoa2309000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。